Sutro Biopharma (STRO) Corporate presentation summary

Platform and technology

• Proprietary cell-free platform enables precise ADC design, optimizing antibody, linker, and payload for improved safety and efficacy.

• Site-selective non-natural amino acid incorporation and ultra-stable linkers enhance tumor selectivity and systemic stability.

• Platform supports both single- and dual-payload ADCs, expanding therapeutic window and reducing toxicity.

• Demonstrates industry-leading ADC exposure and optimized pharmacokinetics in preclinical models.

Pipeline and clinical progress

• Advancing three INDs in two years: STRO-004 (TF-targeting), STRO-006 (ITGB6-targeting), and STRO-227 (PTK7 dual-payload).

• STRO-004 Phase 1 trial ongoing in multiple solid tumors, with next data update expected 1H 2027.

• STRO-006 Phase 1 trial initiation expected in 3Q 2026, targeting integrin beta 6.

• STRO-227 IND submission anticipated in 2026, with dose optimization ongoing.

Clinical data and tolerability

• STRO-004 shows encouraging early clinical activity with confirmed and ongoing partial responses in heavily pretreated patients.

• Favorable tolerability profile across doses, with mostly low-grade adverse events and low discontinuation rates.

• Dose-proportional pharmacokinetics and high stability, maintaining 98% DAR8 configuration and low free payload.